Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
NCT02458287
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Treated with a statin - Fasting LDL-C >=70mg/dL and triglycerides <=400mg/dL
- Pregnant or breastfeeding females - Cardiovascular or cerebrovascular event or
procedures during the past 90 days - Congestive heart failure NYHA class IV - Poorly
controlled hypertension
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Taipei,
- Alexander City, Alabama
- Auburn, Alabama
- Phoenix, Arizona
- Phoenix, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Little Rock, Arkansas
- Little Rock, Arkansas
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Norwalk, California
- Sacramento, California
- Sacramento, California
- Santa Rosa, California
- Tustin, California
- Ventura, California
- Aurora, Colorado
- Colorado Springs, Colorado
- Denver, Colorado
- Boca Raton, Florida
- Boca Raton, Florida
- Brooksville, Florida
- Coral Gables, Florida
- Fort Lauderdale, Florida
- Hialeah, Florida
- Hialeah, Florida
- Miami Beach, Florida
- Miami Lakes, Florida
- Miami Lakes, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miramar, Florida
- Ocala, Florida
- Ocala, Florida
- Pembroke Pines, Florida
- Pembroke Pines, Florida
- Pembroke Pines, Florida
- Port Orange, Florida
- Port Orange, Florida
- Saint Augustine, Florida
- Saint Augustine, Florida
- Saint Petersburg, Florida
- Sarasota, Florida
- Tampa, Florida
- Boise, Idaho
- Avon, Indiana
- Augusta, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Lake Charles, Louisiana
- Metairie, Louisiana
- Monroe, Louisiana
- Bethesda, Maryland
- Elkridge, Maryland
- Flint, Michigan
- Saint Cloud, Minnesota
- Saint Cloud, Minnesota
- Picayune, Mississippi
- Saint Louis, Missouri
- Saint Louis, Missouri
- Fremont, Nebraska
- Portsmouth, New Hampshire
- Albuquerque, New Mexico
- Greenville, North Carolina
- Greenville, North Carolina
- Greenville, North Carolina
- Hickory, North Carolina
- Hickory, North Carolina
- Hickory, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Dayton, Ohio
- Perrysburg, Ohio
- Oklahoma City, Oklahoma
- Tulsa, Oklahoma
- Harleysville, Pennsylvania
- Wyomissing, Pennsylvania
- Charleston, South Carolina
- Columbia, South Carolina
- Spartanburg, South Carolina
- Germantown, Tennessee
- Jackson, Tennessee
- Jackson, Tennessee
- Knoxville, Tennessee
- Carrollton, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Katy, Texas
- Missouri City, Texas
- Plano, Texas
- San Antonio, Texas
- Sugar Land, Texas
- Orem, Utah
- Arlington, Virginia
- Norfolk, Virginia
- Port Orchard, Washington
- Port Orchard, Washington
- Walla Walla, Washington
- Kenosha, Wisconsin
- Manitowoc, Wisconsin
- Calgary, Alberta
- Burnaby, British Columbia
- Kamloops, British Columbia
- Kelowna, British Columbia
- Langley, British Columbia
- New Westminster, British Columbia
- Penticton, British Columbia
- Vancouver, British Columbia
- Victoria, British Columbia
- Barrie, Ontario
- Brampton, Ontario
- Brampton, Ontario
- Corunna, Ontario
- Etobicoke, Ontario
- Markham, Ontario
- Newmarket, Ontario
- Oakville, Ontario
- Oshawa, Ontario
- Peterborough, Ontario
- Scarborough, Ontario
- Thornhill, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Chicoutimi, Quebec
- Greenfield Park, Quebec
- Longueuil, Quebec
- Montreal, Quebec
- Saint-Georges, Beauce, Quebec
- Trois-Rivieres, Quebec
- Trois-Rivieres, Quebec
- Quebec,
- Quebec,
- Trutnov, Kralovehradecky KRAJ
- Praha 10, Vinohrady
- Brno,
- Brno,
- Kladno,
- Kladno,
- Kromeriz,
- Olomouc,
- Olomouc,
- Olomouc,
- Olomouc,
- Praha 4,
- Praha 4,
- Pribram,
- Pribram,
- Slany,
- Slany,
- Teplice,
- Teplice,
- Trutnov,
- Lappeenranta,
- Turku,
- Anyang-si, Gyeonggi-do
- Guri-si, Gyeonggi-do
- Busan,
- Seoul,
- Enschede, ER
- Amsterdam, North Holland
- Apeldoorn,
- Eindhoven,
- Enschede,
- Gorinchem,
- Groningen,
- Heerlen,
- Rotterdam,
- Rotterdam,
- Sneek,
- Tilburg,
- Utrecht,
- Honefoss,
- Oslo,
- Oslo,
- Lublin, Lubelskie
- Zamosc, Lubelskie
- Staszow, Swietokrzyskie
- Gdynia,
- Grodzisk Mazowiecki,
- Katowice,
- Katowice,
- Krakow,
- Lodz,
- Olawa,
- Poznan,
- Pulawy,
- Warszawa,
- Wroclaw,
- Wroclaw,
- Ponce,
- Ponce,
- Rio Grande,
- Singapore,
- Singapore,
- Goteborg,
- Lessebo,
- Linkoping,
- Lund,
- Lund,
- Rattvik,
- Stockholm,
- Stockholm,
- Reading, Berkshire
- Salford, Greater Manchester
- Glasgow, Lanarkshire Scotland
- Chorley, Lancashire
- Hexham, Northumberland
- Worcester, Worcestershire
- Ayr,
- Birmingham,
- Hull,
- Liverpool,
- Manchester,
- Swansea,
- Angers,
- Angers,
- Bordeaux Cauderan,
- Briollay,
- Dijon,
- Hagondange,
- Haut Mauco,
- Jarny,
- Lille,
- Mars LA Tour,
- Metz,
- Monguilhem,
- Mont de Marsan CEDEX,
- Mont de Marsan,
- Mont de Marsan,
- Mont de Marsan,
- Moutiers,
- Murs Erigne,
- Nantes,
- Pouilly en Auxois,
- Saint Justin,
- Saint Martin D'Oney,
- Seysses,
- Strasbourg,
- Thouars,
- Tierce,
- Akersberga,
- Forshaga,
- Goteborg,
- Goteborg,
- Goteborg,
- Hoganas,
- Jonkoping,
- Lessebo,
- Lilla Edet,
- Limhamn,
- Malmo,
- Oviken,
- Partille,
- Stockholm,
- Taby,
- Trollhattan,
- Vasteras,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia | |||
Official Title ICMJE | A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia | |||
Brief Summary | This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen). | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Hyperlipidemia | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 299 | |||
Original Estimated Enrollment ICMJE | 300 | |||
Actual Study Completion Date ICMJE | February 2016 | |||
Actual Primary Completion Date | February 2016 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02458287 | |||
Other Study ID Numbers ICMJE | B1481046 SPIRE-AI ( Other Identifier: Alias Study Number ) | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2017 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |